Marksans Pharma Limited — Updates, 25-02-2025: Press Release

Marksans Pharma Limited's wholly-owned UK subsidiary, Relonchem Limited, has received Marketing Authorization for its Ibuprofen and Paracetamol 200 mg/500 mg Film-coated Tablets, branded as Bell's Healthcare Dual Action Pain Relief. This approval enhances Marksans' product portfolio in the pain management segment and opens avenues for expansion in the UK market. The successful launch of this product could significantly contribute to revenue growth, given the increasing demand for pain relief medications. Investors should monitor this development closely, as it reflects positively on Marksans' operational capabilities and strategic direction in global markets.